Cell compound type reconstructed extracellular matrix hydrogel patch and construction method and application of humanized liver animal model

Through the preparation of cell-complex reconstituted extracellular matrix hydrogel patches, a complex of functional hepatocyte-like cells and mesenchymal stem cells was constructed, which solved the low efficiency and high risk of humanized liver construction in the prior art. The problem has achieved efficient and safe liver regeneration and inflammation repair, providing a stable liver disease research and treatment model.

CN118948898AInactive Publication Date: 2024-11-15ANHUI BLACK BEAN BIOTECHNOLOGY CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411014704.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing humanized liver construction methods are inefficient, have high risks and are unstable, and cannot effectively promote the regeneration and repair of liver tissues in liver failure, and cannot block the inflammatory factor storm from the root, limiting the effectiveness of liver disease treatment.

Method used

Using the preparation method of cell-complex reconstituted extracellular matrix hydrogel patch, through decellularization and maturation induction technology, a complex of functional hepatocyte-like cells and mesenchymal stem cells is constructed to form a complex that can secrete cytokines and regulate Cell-complex hydrogel patches for immune responses are used to construct humanized liver animal models.

Benefits of technology

It achieves efficient, safe and stable liver tissue regeneration and inflammation repair, reduces hepatocyte apoptosis, promotes the recovery of liver function, and provides a safe and stable humanized liver model for liver disease research and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948898A_ABST
    Figure CN118948898A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, and particularly discloses a cell compound type reconstructed extracellular matrix hydrogel patch and a construction method and application of a humanized liver animal model. The cell compound type reconstructed extracellular matrix hydrogel patch has good hydromechanics, thermosensitivity and antibacterial performance, the contained compound cell aggregate of MSCs and HLCs can secrete a large number of cell factors, activation of natural immune cells is inhibited by adjusting a molecular signal channel, inflammation infiltration is relieved, and the cell compound type reconstructed extracellular matrix hydrogel patch has the advantages of being good in biocompatibility, good in biocompatibility and good in biocompatibility. In addition, by activating cells of an adaptive immune system, a tolerant environment is created for maintaining in-vivo immune dynamic balance, liver cell apoptosis is reduced, and liver regeneration is promoted. The humanized liver constructed by adding the cell compound type reconstructed extracellular matrix hydrogel patch is more efficient, safer and more stable, and has important theoretical and application values for liver disease treatment and research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biotechnology, and in particular to a method for constructing and applying a cell-complex reconstructed extracellular matrix hydrogel patch and a humanized liver animal model. Background Art

[0002] Liver disease refers to lesions that occur in the liver. There are many types of liver diseases, including hepatitis A, hepatitis B, hepatitis C, fatty liver disease, liver cancer, cirrhosis, alcoholic or non-alcoholic liver disease, etc. Liver disease is an important factor leading to cirrhosis and liver failure. Continuous inflammation and persistent apoptosis of liver cells activate hepatic stellate cells, accelerate the formation of liver fibrosis, and eventually lead to cirrhosis and ultimate liver failure. Liver failure is a multifaceted clinical syndrome characterized by various manifestations, including but not limited to jaundice, coagulopathy, and multiple organ dysfunction in the late stage.

[0003] There are currently a variety of treatment options available clinically. Orthotopic liver transplantation is currently the most effective and mature method for treating liver failure, but its use is limited due to liver shortages, high costs, and the requirement for lifelong immunosuppression. In addition, there are some new treatments used to treat liver failure-related liver dysfunction compensation, including hepatocyte transplantation, plasma exchange, bioartificial liver, etc., which can partially improve the systemic symptoms caused by liver damage and alleviate the course of the disease to a certain extent. However, because these methods are actually a liver replacement strategy, they cannot improve local inflammatory infiltration in the liver, and cannot block the generation of inflammatory factor storms from the root, prolonging the treatment time and limiting the treatment effect.

[0004] For the above liver diseases, constructing a humanized liver is a technical method with important research and application value. In addition to being used to study the toxic mechanism of hepatotoxic drugs, it can also be directly used for liver function replacement therapy research for liver failure. However, the existing method for constructing a humanized liver is mainly to inject liver cells directly into the animal body, which is inefficient and risky, and the constructed humanized liver model is unstable. Therefore, based on the current status of existing technologies, a humanized liver construction method that is efficient, safe, stable, and can promote the regeneration and repair of liver tissue in liver failure is currently needed. Summary of the invention

[0005] The purpose of the present application is to overcome the deficiencies of the above-mentioned prior art and to provide a method for constructing and applying a cell-complex reconstructed extracellular matrix hydrogel patch and a humanized liver animal model.

[0006] To achieve the above purpose, the technical solution adopted by this application is:

[0007] The present application provides a method for preparing a cell-complex reconstructed extracellular matrix hydrogel patch, comprising the following steps:

[0008] S1, taking a tissue block, performing a decellularization treatment on the tissue block to obtain a decellularized scaffold, freeze-drying and grinding the decellularized scaffold to obtain an extracellular matrix powder; digesting the extracellular matrix powder in a digestive solution, and adding oligourethane to mix to obtain a pregel;

[0009] S2, pre-treating the mesenchymal stem cells, and inducing the pre-treated mesenchymal stem cells to become hepatogenic using the hepatogenic induction composition;

[0010] Using a first maturation induction composition to perform a first maturation induction on the mesenchymal stem cells that have been subjected to hepatogenesis induction treatment, to obtain hepatocyte-like cells HLCs; using a second maturation induction composition to perform a second maturation induction on the hepatocyte-like cells HLCs, to obtain functional hepatocyte-like cells;

[0011] S3. Evenly mix the pregel prepared in step S1, mesenchymal stem cells and the functional hepatocyte-like cells prepared in step S2, let stand to solidify, and wait for the functional hepatocyte-like cells to aggregate to form spheres, thereby obtaining a cell-composite reconstructed extracellular matrix hydrogel patch.

[0012] In the technical scheme of the present application, the cell composite reconstructed extracellular matrix hydrogel patch prepared by the present application not only has good fluid mechanics, temperature sensitivity and antibacterial properties, but also contains composite cell aggregates of MSCs and HLCs which can secrete a large number of cytokines, reduce inflammatory infiltration by regulating molecular signaling pathways and inhibiting the activation of natural immune cells, and can also activate cells of the adaptive immune system to create a tolerant environment for maintaining the immune homeostasis in the body, reduce hepatocyte apoptosis, and promote liver regeneration. And because of the various bioactive molecules of the extracellular matrix contained therein, it is conducive to the adhesion and growth of cells, which is of great benefit to the repair of inflammation after treatment and the reconstruction of tissues. The humanized liver constructed in this way is more efficient, safe, and stable, and has important theoretical and application value for the research on the treatment of liver diseases.

[0013] Mesenchymal stem cells (MSCs)-mediated organ repair and regeneration have attracted much attention for their inherent self-replication and multidirectional differentiation capabilities as well as their good anti-tumor repair capabilities. MSCs have the advantages of abundant donor cell sources, less surgical damage, less immune rejection, low cost, and good safety. This experiment innovatively extracted homologous MSCs from human umbilical cords and co-cultured them with functional hepatocyte-like cells (HLCs) to form cell aggregates. By constructing a cell-complex reconstructed extracellular matrix hydrogel patch, human cells can be effectively and safely and stably filled into the damaged liver of mice, realizing the construction of a humanized model of FRG immunodeficient mice. In addition to being used to construct a humanized liver research model, the idea of ​​this technical solution can also be used to construct models of other humanized organs, which will open up new directions for the construction of humanized livers and the treatment of liver diseases.

[0014] Preferably, the tissue block is an umbilical cord tissue block; the mesenchymal stem cells are human umbilical cord-derived mesenchymal stem cells; and the functional hepatocyte-like cells are functional human hepatocyte-like cells.

[0015] This application uses umbilical cord as a tissue material for preparing a cell-complex reconstructed extracellular matrix hydrogel patch. The umbilical cord has special properties as human tissue medical waste, and the source is sufficient, and does not involve species and ethical issues. Extracellular matrix (ECM) is a biological network structure composed of macromolecules. It is a natural biological derivative material after the cell components in the biological tissue are removed by physical and chemical methods. The main components are collagen, non-collagen, elastin, proteoglycan, aminoglycan and some biologically active substances in natural tissues. It can provide physical support and a suitable place for cell growth, promote cell adhesion, growth, proliferation and differentiation and regeneration of damaged tissues and organs. The human umbilical cord extracellular matrix hydrogel extracted by the present application, after decellularization and reconstruction, can effectively preserve the physicochemical signals and biological properties of ECM, provide mechanical support substrate and biological 3D carrier for cell inoculation, and the porous mesh structure presented inside is conducive to the attachment and migration of regenerative cells, and can provide the most suitable growth and proliferation microenvironment for umbilical cord-derived MSCs, and the thermosensitive characteristics can be gel-formed under the action conditions of body temperature, which is conducive to the targeted delivery and slow-controlled release of the attached drug, and is rich in proteins (apolipoprotein, HSP90, ANXA1-A6, etc.) that promote the paracrine effect of cells. By constructing a cell composite reconstructed extracellular matrix hydrogel patch, the retention rate and action time of cells in the target site after entering the body are greatly improved, so that cells can maintain their activity and long-term activation in the body, and better play the role of constructing humanized liver. It can be gelled at human body temperature, has the advantages of safety, high efficiency, strong controllability, and is easy to degrade in the body without causing strong immune rejection. The raw material human umbilical cord is a natural source, which reduces the risk of rejection and can eventually degrade by itself.

[0016] As a preferred embodiment of the method for preparing the cell-complex reconstructed extracellular matrix hydrogel patch of the present application, the decellularization treatment in step S1 includes:

[0017] The tissue blocks were decellularized using a mixed solution of trypsin and ethylenediaminetetraacetic acid, a camptothecin solution containing penicillin / streptomycin, a sulfobetaine solution, ethylenediaminetetraacetic acid, a mixed solution of DNase and RNase, sodium dodecyl sulfate, Triton X and sodium deoxycholate to obtain a decellularized scaffold.

[0018] As a preferred embodiment of the preparation method of the cell composite reconstructed extracellular matrix hydrogel patch described in the present application, the mass concentration of pancreatic enzyme in the mixed solution of pancreatic enzyme and ethylenediaminetetraacetic acid is 0.02%, and the mass concentration of ethylenediaminetetraacetic acid is 0.05%; the mass concentration of camptothecin in the camptothecin solution containing penicillin / streptomycin is 20 μM; the mass concentration of the sulfobetaine solution is 125 mM; the final concentration of DNA enzyme in the mixed solution of DNA enzyme and RNA enzyme is 0.1%, and the final concentration of RNA enzyme is 0.05%; the mass concentration of sodium dodecyl sulfate is 0.1%; the mass concentration of Triton X-100 is 3% and the mass concentration of sodium deoxycholate is 4%.

[0019] The present application establishes a combined scheme of using a mixed solution of pancreatic enzyme and ethylenediaminetetraacetic acid at the above-mentioned concentration, a camptothecin solution containing penicillin / streptomycin, a sulfobetaine solution, ethylenediaminetetraacetic acid, a mixed solution of DNase and RNase, sodium dodecyl sulfate, Triton X and sodium deoxycholate to efficiently extract decellularized extracellular matrix from umbilical cord tissue, and only takes 1-2 days to obtain a high-quality decellularized scaffold, and 6-7 days to obtain a hydrogel, and the integrity of the internal structure of the extracellular matrix is ​​retained to the greatest extent.

[0020] Preferably, in step S1, before freeze-drying and grinding the decellularized scaffold, the decellularized scaffold is placed in a solution of 75% alcohol and 0.1% peracetic acid for immersion and disinfection, and then washed with PBS and water in sequence.

[0021] Preferably, in step S1, the digestive solution includes a solution of pepsin hydrochloride, and the extracellular matrix powder is placed in the digestive solution for digestion until no powdery material is visible to the naked eye.

[0022] Preferably, in step S1, the concentration of the oligourethane is 1.2 mg / ml.

[0023] The present application adds 15 wt.% of oligourethane, which can better induce the collagen in the decellularized ECM to polymerize at human body temperature to form a hydrogel network, making it gel faster and more firmly cross-linked.

[0024] As a preferred embodiment of the method for preparing the cell-complex reconstructed extracellular matrix hydrogel patch described in the present application, in step S2, the reagents for pre-treating the mesenchymal stem cells include 20 ng / mL of epidermal growth factor and 10 ng / mL of basic fibroblast growth factor.

[0025] As a preferred embodiment of the method for preparing the cell composite reconstructed extracellular matrix hydrogel patch described in the present application, the hepatogenesis induction composition includes 30 ng / mL basic fibroblast growth factor, 20 ng / mL hepatocyte growth factor and 0.61 g / L nicotinamide;

[0026] The first maturation induction composition includes 40 ng / mL of ITS Premix, 10 ng / mL of recombinant human osteoprotegerin-M and 1 μmol / L of dexamethasone;

[0027] The second maturation induction composition includes 40 ng / mL of ITS Premix, 40 ng / mL of recombinant human osteoprotegerin-M, 1 μmol / L of dexamethasone, 10 μmol / L of human γ-secretase complex inhibitor and 10 μmol / L of small molecule inhibitor SB431542.

[0028] Under an optical microscope, the functional hepatocyte-like cells are irregularly round or polygonal, with clear nucleolar boundaries. The liver-specific gene expression rate of the functional hepatocyte-like cells is higher than that of the liver cells. Specifically, the liver-specific genes include alpha-fetoprotein, albumin and cytokeratin. The glycogen accumulation function of the functional hepatocyte-like cells is positive.

[0029] In the technical solution of the present application, the hepatogenesis induction composition, the first maturation induction composition and the second maturation induction composition used only contain factors and small molecule compounds, and have a simple formula and are easy to prepare.

[0030] The method of reprogramming umbilical cord mesenchymal stem cells into functional hepatocyte-like cells of the present application adds a second maturation induction step, prolongs the culture time, and significantly improves the induction efficiency, especially the albumin expression of the obtained functional hepatocyte-like cells is significantly increased.

[0031] The method for reprogramming umbilical cord mesenchymal stem cells into functional hepatocyte-like cells of the present application adds an inhibitor to the second maturation induction composition, inhibits bypass signal transduction, and thus promotes the differentiation of mesenchymal stem cells into functional hepatocyte-like cells.

[0032] Preferably, in step S2, the time for hepatogenesis induction is 7 days, the time for the first maturation induction is 7 days, and the time for the second maturation induction is 12 to 20 days.

[0033] As a preferred embodiment of the method for preparing the cell composite reconstructed extracellular matrix hydrogel patch of the present application, in step S3, the cell density ratio of the mesenchymal stem cells and the functional hepatocyte-like cells prepared in step S2 is 9×10 6 pcs:1×106 indivual.

[0034] The reason for adding human umbilical cord-derived mesenchymal stem cells to the mixture in this application is that due to the immunomodulatory properties of MSCs, the cell-composite reconstructed extracellular matrix hydrogel has ultra-low immunogenicity, and the constructed cell-composite reconstructed extracellular matrix hydrogel will not cause immune response when transplanted between different individuals, and can even be transplanted across species, and it is low-cost, widely available, can be mass-produced, the system is mature and easy to replicate, and the effect is stable, which lays the foundation for future clinical trials. Further, the liver organoids were transplanted into rats, and the rats were dissected 10 days after transplantation. It can be seen that the grafts migrated to the surface of the liver, and the cell-composite reconstructed extracellular matrix hydrogel was covered with blood vessels, indicating that the human-derived cell-composite reconstructed extracellular matrix hydrogel can be maintained and grown in rats without causing immune rejection.

[0035] As a preferred embodiment of the method for preparing the cell-complex reconstructed extracellular matrix hydrogel patch of the present application, in the step S3, the pregel prepared in step S1, the mesenchymal stem cells and the functional hepatocyte-like cells prepared in step S2 are mixed evenly with a serum-free culture medium;

[0036] The volume ratio of the serum-free culture medium to the pregel is (1-3):(2-4), preferably 3:4.

[0037] The present application also provides a cell-composite reconstructed extracellular matrix hydrogel patch prepared by the preparation method of the above-mentioned cell-composite reconstructed extracellular matrix hydrogel patch.

[0038] The cell-composite reconstructed extracellular matrix hydrogel patch obtained in the present application can be used in a variety of 3D culture systems of stem cells and organoids. Because it is obtained by reconstructing the extracellular matrix, its physical properties such as particle size, porosity, modulus, etc. can be freely controlled to adapt to different cell culture requirements and different treatment environment needs.

[0039] The present application also provides a method for constructing a humanized liver animal model, wherein the cell-complex reconstructed extracellular matrix hydrogel patch is transferred in vivo into an FRG immunodeficient animal to obtain a humanized liver animal model.

[0040] The present application implants the prepared cell-complex reconstructed extracellular matrix hydrogel patch into liver-injured mice to obtain a humanized liver animal model. The construction method can replace the damaged liver cells of the liver of FRG immunodeficient mice and improve the liver function impairment and liver metabolic diseases caused by Fah gene deficiency by filling the damaged liver of FRG (Fah- / -Rag- / -IL2rg- / -) mice with human umbilical cord-derived MSCs and reprogrammed HLCs, and reproduce some of the liver functions. The construction method of the present application has the advantages of safety, high efficiency, and strong controllability, and avoids the use of liver resection surgery, liver injury drugs, viruses, bacteria, etc. in the construction process, which may interfere with subsequent applications.

[0041] The reconstructed extracellular matrix contains a variety of proteins and bioactive molecules, which are beneficial to improve the activity of stem cells, maintain their stemness, greatly improve the retention rate of stem cells in the body, and achieve a long-term repair effect. The reconstructed extracellular matrix hydrogel can freely control the shape and related physical and chemical parameters to adapt to different application scenarios. The effect of cell-complex reconstructed extracellular matrix hydrogel patch transplantation to construct a humanized liver is significantly better than a single cell intravenous or intrasplenic injection, with higher safety, and can effectively fill human cells into the damaged liver of mice to achieve the effect of functional replacement. This construction method has a significant promoting effect on the regeneration and repair of liver tissue in animals with liver damage. In addition to being used to construct a humanized liver model, the idea of ​​this technical solution can also be used to construct models of other humanized organs. This technical solution provides a safe, stable and efficient humanized liver model for clinical liver disease treatment research, and has important theoretical and application value for liver disease treatment research.

[0042] The present application also provides the use of a cell-complex reconstructed extracellular matrix hydrogel patch in the preparation of a product for treating liver failure.

[0043] Compared with the prior art, this application has the following beneficial effects:

[0044] The present application provides a method and application for constructing a cell-composite reconstructed extracellular matrix hydrogel patch and a humanized liver animal model. The cell-composite reconstructed extracellular matrix hydrogel patch not only has good fluid mechanics, temperature sensitivity and antibacterial properties, but also contains a composite cell aggregate of MSCs and HLCs that can secrete a large amount of cytokines, reduce inflammatory infiltration by regulating molecular signaling pathways and inhibiting the activation of natural immune cells, and can also activate cells of the adaptive immune system to create a tolerant environment for maintaining the immune homeostasis in the body, reduce hepatocyte apoptosis, and promote liver regeneration. And because of the various bioactive molecules of the extracellular matrix contained therein, it is conducive to the adhesion and growth of cells, which is of great benefit to the repair of inflammation after treatment and the reconstruction of tissues. The humanized liver constructed in this way is more efficient, safe, and stable, and has important theoretical and application value for the treatment of liver diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 The intermediate product and finished product of the cell-composite reconstructed extracellular matrix hydrogel patch prepared in Example 1 (a is umbilical cord tissue cut into small pieces; b is a decellularized scaffold; c is extracellular matrix powder; de is a picture of different morphologies of pre-gel; f is a picture of the phase transition process of the pre-gel from liquid to gel);

[0046] Figure 2 This is a scanning electron microscope image (SEM) of the cell-complex reconstructed extracellular matrix hydrogel patch prepared in Example 1;

[0047] Figure 3 This is a diagram of the elastic modulus of the cell-complex reconstructed extracellular matrix hydrogel patch precursor (without cells added in the early stage) prepared in Example 1;

[0048] Figure 4 This is a comparison chart of the DNA content of the cell-complex reconstructed extracellular matrix hydrogel patch precursor (without adding cells in the early stage) prepared in Example 1;

[0049] Figure 5 HE staining and Masson staining of tissue sections of the cell-complex reconstructed extracellular matrix hydrogel patch prepared in Example 1;

[0050] Figure 6 This is a diagram showing the cell survival status of the cell composite reconstructed extracellular matrix hydrogel patch prepared in Example 1;

[0051] Figure 7 This is a diagram showing an example of transplantation of the cell-complex reconstructed extracellular matrix hydrogel patch prepared in Example 1 for the treatment of liver failure;

[0052] Figure 8This is a graph showing the survival rate and weight change of mice using the cell-complex reconstructed extracellular matrix hydrogel patch prepared in Example 1 to treat liver failure;

[0053] Fig. 9 The changes in liver function of mice treated with the cell-complex reconstructed extracellular matrix hydrogel patch prepared in Example 1 for liver failure;

[0054] Fig.10 This is an immunofluorescence image of a tissue section of the cell-complex reconstructed extracellular matrix hydrogel patch prepared in Example 1;

[0055] Fig.11 HE staining of mouse liver tissue sections after transplantation of the cell-complex reconstructed extracellular matrix hydrogel patch prepared in Example 1 for treating liver failure in mice;

[0056] Fig.12 This is an immunohistochemical image of mouse liver tissue sections after transplantation of the cell-complex reconstructed extracellular matrix hydrogel patch prepared in Example 1 for treating liver failure in mice;

[0057] Fig.13 This is the immunohistochemistry image of mouse liver tissue sections after transplantation of the cell-composite reconstructed extracellular matrix hydrogel patch prepared in Comparative Example 1 for the treatment of liver failure in mice. DETAILED DESCRIPTION

[0058] In order to better illustrate the purpose, technical solutions and advantages of the present application, the present application will be further described below in conjunction with the accompanying drawings and specific embodiments.

[0059] In the following examples and comparative examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.

[0060] In the following examples, the reagents used for pre-treating mesenchymal stem cells include 20 ng / mL of epidermal growth factor and 10 ng / mL of basic fibroblast growth factor.

[0061] The following hepatogenesis induction composition includes 30 ng / mL of basic fibroblast growth factor, 20 ng / mL of hepatocyte growth factor, and 0.61 g / L of nicotinamide.

[0062] The following first maturation induction composition includes 40 ng / mL of ITS Premix, 10 ng / mL of recombinant human osteoprotegerin-M and 1 μmol / L of dexamethasone;

[0063] The following second maturation induction composition includes 40 ng / mL of ITS Premix, 40 ng / mL of recombinant human osteoprotegerin-M, 1 μmol / L of dexamethasone, 10 μmol / L of human γ-secretase complex inhibitor and 10 μmol / L of small molecule inhibitor SB431542.

[0064] The serum-free culture medium used for extracting, culturing and diluting umbilical cord mesenchymal stem cells is composed of DMEM basal culture medium, 20 ng / ml recombinant human stem cell growth factor (rhSCF), 15 ng / ml epidermal growth factor (EGF), 20 ng / ml basic fibroblast growth factor (bFGF), 15 ng / ml transforming growth factor-β (TGF-β), 10 ng / ml platelet-derived growth factor-BB (PDGF-BB), 10 mg / L recombinant human insulin, 20 mg / L recombinant human transferrin, 1.5 g / L recombinant human serum albumin (rHSA) and 10 μg / ml fibronectin.

[0065] Example 1: A cell-complex reconstructed extracellular matrix hydrogel patch and its preparation method

[0066] This embodiment provides a method for preparing a cell-complex reconstructed extracellular matrix hydrogel patch, comprising the following steps:

[0067] (1) crushing human umbilical cord tissue to obtain tissue blocks; specifically, after obtaining fresh umbilical cord tissue, repeatedly washing the umbilical cord with physiological saline containing 1% penicillin-streptomycin, and testing the tissue blocks for viruses, bacteria, and mycoplasma to ensure that the decellularized matrix hydrogel prepared subsequently is free of microbial contamination; after confirming that the tissue blocks meet the requirements, washing the surface with deionized water, removing the arteries and veins of the umbilical cord, squeezing out blood and blood clots, cutting the umbilical cord into small segments of 3-4 cm, and placing them in a tissue crusher and stirring at a speed of 300 rpm to obtain tissue blocks of about 3 mm*3 mm in size;

[0068] The tissue blocks were then subjected to the following decellularization steps in sequence: transferred to a mixed solution containing 0.02% pancreatin and 0.05% ethylenediaminetetraacetic acid, stirred at 350 rpm for 2-3 h at 37°C; the tissues were washed with deionized water 3 times, 10 min each time; the tissue blocks were transferred to a 20 μM camptothecin (Sigma-Aldrich C9911) solution containing 1% penicillin / streptomycin, and incubated at 37°C for 48 h under stirring; the tissue blocks were transferred to sterile hypertonic (4×) PBS for rinsing 3 times, 10 min each time; the tissue blocks were transferred to 125 mM sulfobetaine-10 (sulfobetaine-10SB-10, Sigma-Aldrich D4266), incubated overnight at 37°C under stirring; the tissue block was transferred into a sterile isotonic (1×) PBS solution for rinsing 3 times, each time for 10 minutes; then the tissue block was transferred into a DNAseⅠ / RNase A mixed solution, wherein the final concentrations of DNAse and RNAse were 0.1% and 0.05%, respectively. Stirred at 350 rpm for 2-3 hours at 37°C, and then rinsed with PBS 3 times; then the tissue block was transferred into 0.1% sodium dodecyl sulfate (SDS), stirred at 250 rpm for 1 hour at 37°C; then the tissue block was transferred into deionized water for washing 3 times, each time for 10 minutes; then the tissue block was transferred into a mixed solution containing 3% Triton X and 4% sodium deoxycholate, stirred at 250 rpm for 1 hour at 37°C; the tissue block was transferred into deionized water, and soaked at 27°C for 12-18 hours to obtain a decellularized scaffold. The decellularized scaffold is moved into 75% alcohol, soaked for 30 minutes, and then moved into a solution containing 0.1% peracetic acid, and stirred at a speed of 150 rpm for 2 to 3 hours; a white, porous decellularized matrix scaffold is obtained from the umbilical cord tissue.

[0069] (2) freeze-drying and cryogenically grinding the decellularized scaffold washed in step (1) to obtain an extracellular matrix powder. Specifically, the decellularized scaffold is placed in a -80°C environment for 3 to 4 hours, transferred to a freeze dryer for freeze drying, and transferred to a grinder pre-cooled with liquid nitrogen for grinding, the grinding frequency of the grinder is 60 Hz, and the grinding time is 120 seconds.

[0070] (3) The extracellular matrix powder of step (2) was transferred into a solution of pepsin hydrochloride and stirred for digestion until no powdery substance was visible to the naked eye, and 10 mg of the extracellular matrix powder was added to every 1 ml of pepsin hydrochloride solution; oligourethane (final concentration of 1.2 mg / ml (15 wt.%)) was added to the mixed digestion solution and mixed, and vortexed for 30 seconds to obtain a pre-gel;

[0071] (4) Obtaining umbilical cord mesenchymal stem cells; pre-treating the umbilical cord mesenchymal stem cells for 2 days (prior to the pre-treatment, culturing in vitro under serum-free conditions to the logarithmic growth phase); inducing the pre-treated umbilical cord mesenchymal stem cells into hepatogenesis for 7 days using a hepatogenesis induction composition; performing a first maturation induction on the umbilical cord mesenchymal stem cells that have been subjected to hepatogenesis induction treatment using a first maturation induction composition for 7 days to obtain hepatocyte-like cells (HLCs); performing a second maturation induction on the liver cells using a second maturation induction composition for 12 to 20 days to obtain functional hepatocyte-like cells.

[0072] (5) Add 10×PBS at low temperature and mix well to dilute the pregel to a preset concentration (10 mg / ml), adjust the pH to neutral (the pregel needs to be neutralized with phosphate buffer and sodium hydroxide before being used to culture cells and prepare organoids), and mix the diluted pregel with umbilical cord mesenchymal stem cells and functional hepatocyte-like cells in serum-free medium (specifically, the mixing ratio of the decellularized matrix hydrogel dilution, umbilical cord mesenchymal stem cells and functional hepatocyte-like cells is: 9×10 6 umbilical cord mesenchymal stem cells, 1×10 6 Functional hepatocyte-like cells and 20 ml diluted pre-gel. That is, the ratio of culture medium to hydrogel is 3 to 4, and the ratio of stem cells to reprogrammed hepatocyte-like cells is 9 to 1); then, the pre-gel is cultured in a culture container at 37°C and 5% CO2 until the pre-gel solidifies;

[0073] (6) After confirming the survival of the cells in the solidified pregel, the cells are cultured for 6-7 days until the cells aggregate to form spheres, thereby obtaining a cell-complex reconstructed extracellular matrix hydrogel patch. In this embodiment, the survival of mesenchymal stem cells and reprogrammed liver cells in the pregel can be confirmed by staining.

[0074] in, Figure 1 a in the figure is the umbilical cord tissue cut into small pieces; Figure 1 b in the figure is a decellularized scaffold; Figure 1 c in it is extracellular matrix powder; Figure 1 de in the figure are different morphological diagrams of pre-gel; Figure 1 Figure f is a phase transition diagram of the pregel from liquid to gel.

[0075] The SEM scanning electron microscope image of the cell composite reconstructed extracellular matrix hydrogel patch prepared in this example is as follows: Figure 2 shown.

[0076] The elastic modulus and DNA content of the pregel prepared in step (3) were measured as follows: Figure 3-4 shown.

[0077] The specific tests are:

[0078] 1. Test the elastic modulus of pre-gel:

[0079] The oscillatory rheology of the pre-gel obtained in step (3) was measured with a HAAKE MARS 40 thermal rheometer. 1 mL of ECM pre-gel was confined between two plates, each of which was 20 mm in size and 1 mm in gap. The test was carried out at a temperature of 37° C., with a test frequency of 1-39.81 rad / S and a test deformation of 0.1%-100%. A constant sinusoidal stress of 0.5 pA was applied at 1 Hz (6.28 rad / S), with a maximum amplitude. The strain measured was 90 minutes.

[0080] 2. Test the DNA content of the pre-gel:

[0081] Sample acquisition and processing: The tissue was broken into pieces and prepared into a suspension.

[0082] Fixation: Tissues are fixed with ethanol (usually 70%) to stabilize the DNA and make it accessible for staining.

[0083] Staining: Choose an appropriate DNA-specific dye (such as propidium iodide (PI) or DAPI) to stain the tissue.

[0084] Washing: Wash the fixed tissue in an appropriate buffer to remove excess fixative and unbound dye.

[0085] Staining: Incubate the tissue with the DNA dye in the dark for a period of time to ensure adequate binding of the dye to the DNA.

[0086] Wash: Wash the tissue again to remove unbound dye.

[0087] Loading: Load the stained tissue suspension into the flow cytometer.

[0088] Data Collection: Data is collected using a flow cytometer. Typically fluorescence intensity is measured, which reflects DNA content.

[0089] HE staining and Masson staining of tissue sections of the cell-complex reconstructed extracellular matrix hydrogel patch prepared in this example are shown in FIG. Figure 5 shown.

[0090] Hematoxylin and eosin staining and Masson staining: Fresh tissue blocks, decellularized tissue blocks, and the cell-complex reconstructed extracellular matrix hydrogel patch prepared in this example were extracted at concentrations of 2 mg / mL and 10 mg / mL, respectively. Tissue specimens were fixed with 4% paraformaldehyde, embedded in paraffin, and sliced ​​to 7 μm thickness. The slices were stained with H&E and Masson staining to evaluate the amount of cell nucleus removal and the amount of collagen retained, respectively. The staining procedure was performed (Thermo Fisher).

[0091] The cell survival of the cell composite reconstructed extracellular matrix hydrogel patch prepared in this example is shown in the figure below: Figure 6 shown.

[0092] As described in (6) of Example 1, the survival rate of cells cultured in the cell-complex reconstructed extracellular matrix hydrogel was determined by evaluating the calcein AM / PI-stained (live / dead) cells on days 1, 3, and 7 (n=3).

[0093] Cell preparation: Grow the cells to be tested to an appropriate density and ensure that the cells are in the logarithmic growth phase.

[0094] Dye preparation: Prepare working solutions of live and dead cell dyes. These dyes are diluted to appropriate concentrations in serum-free medium.

[0095] Staining: Incubate cells with the cell dye in the dark for a set period of time, usually 5-15 minutes.

[0096] Wash: Wash cells with serum-free medium to remove unbound dye.

[0097] Observation or analysis: Use a fluorescence microscope to observe cells. Live cells will emit green fluorescence (produced by live cell dyes), while dead cells will emit red fluorescence (produced by dead cell dyes). Load the cells into a flow cytometer and distinguish live cells from dead cells by the fluorescent signal.

[0098] Data analysis: Calculate the ratio of live cells to dead cells to obtain the cell viability.

[0099] Example 2

[0100] Compared with Example 1, the difference is that the ratio of culture medium to hydrogel is 1:2, and the remaining steps and reagents are the same as those in Example 1. A cell-complex reconstructed extracellular matrix hydrogel patch is prepared.

[0101] Comparative Example 1

[0102] Compared with Example 1, the difference is that primary human hepatocytes are used to replace the prepared functional hepatocyte-like cells, and the remaining steps and reagents are the same as in Example 1.

[0103] Compared with Example 1, under the same conditions, the primary human hepatocytes used in this comparative example are more difficult to obtain and have higher immunogenicity, which reduces the efficiency of cell implantation in mouse livers (e.g. Fig.13 shown).

[0104] Verification test

[0105] Step 1: Establishment of mouse liver failure model:

[0106] Unmated male FRG mice (20-22 g, 8 weeks old) were housed in an SPF barrier system at a temperature of 20-26°C and a humidity of 50%-60%, and were fed ad libitum. They were randomly divided into 5 groups (n=13):

[0107] Group 1, mice were deprived of NTBC (nitisinone) supply (NTBC-);

[0108] Group 2, mice were deprived of NTBC supply and transplanted with HLC cells (HLCs);

[0109] Group 3, mice were deprived of NTBC supply and transplanted with hydrogel / mesenchymal stem cells (hydrogel / MSCs);

[0110] In group 4, mice were deprived of NTBC supply and transplanted with the cell-complex reconstructed extracellular matrix hydrogel patch prepared in Example 1 (transplantation diagram as shown in FIG. Figure 7 shown);

[0111] Group 5, mice were maintained with NTBC supply (NTBC+).

[0112] FRG mice were maintained with drinking water containing NTBC (16 μg / ml). NTBC concentration was reduced from drinking water according to a stepwise schedule of 100%, 25%, 12%, 6% and 0%. One day before transplantation, mice received an injection of 100 μl UPA (Hanbio Biotechnology Co Ltd HH20210403GYQ-AP01) per animal.

[0113] Step 2: Transplant the cell-complex reconstructed extracellular matrix hydrogel patch into the median lobe of the liver of FRG mice in vivo.

[0114] Step 3: Evaluation of the therapeutic effect of mouse liver failure: The body weight of FRG mice was measured every 3 days after transplantation. The body weight at the designated time point was normalized to the body weight at the beginning of the experiment. Surviving recipient mice were sacrificed 3 months after transplantation to collect blood and liver samples for further analysis.

[0115] (1) Mice in group 1 lost weight and all died of liver failure within 4 weeks, mice in group 2 had partial repopulation and liver function recovery, and transplants in groups 3-4 had partial liver function replacement, symptoms were alleviated, and mortality was reduced ( Figure 8-Figure 9 ).

[0116] (2) Immunofluorescence staining with human-specific (hALB) and Fah antibodies detected hALB / Fah-positive human cells in the mouse liver, and hALB / Fah-positive cells were also positive for cytokeratin 18 (CK18). The immunohistochemical results were consistent with the immunofluorescence results ( Fig.10 ), confirming that human cells repopulate the liver parenchyma of surviving mice, indicating that HLCs can repopulate the liver of FRG mice and improve the impaired liver function caused by Fah deficiency.

[0117] (3) The serum ALT and AST levels of the surviving recipients were significantly reduced, indicating that liver function was improved. HE staining showed that a large number of hepatocytes were observed in Group 5 (NTBC+) with almost no inflammatory cell infiltration, while Group 1 (NTBC-) had severe liver damage, a sharp decrease in hepatocytes, and a large number of infiltrating inflammatory cells. When the cell-complex reconstructed extracellular matrix hydrogel patch was transplanted into mice, liver damage was significantly alleviated, and a large number of normal hepatocytes were observed, but there was still a small amount of inflammatory cell infiltration ( Fig.11 ), cell-complex reconstructed extracellular matrix hydrogel patch transplantation can significantly improve Fah deficiency-induced liver metabolic diseases. Immunohistochemistry results showed that human cells were successfully implanted in the liver of FRG mice, successfully achieving humanized liver to replace the damaged liver of mice ( Fig.12 ). The effect of the composite cells was significantly better than that of single cells. The cell composite reconstructed extracellular matrix hydrogel patch did not form tumors in FRG mice 3 months after transplantation.

[0118] The results of the cell-complex reconstructed extracellular matrix hydrogel patch prepared in Example 2 were similar to those in Example 1.

[0119] In summary, these results strongly support that the cell-composite reconstructed extracellular matrix hydrogel patch has significant in vivo implantation and maturation capabilities, and provide evidence for the therapeutic effect of the cell-composite reconstructed extracellular matrix hydrogel patch in constructing humanized liver and treating metabolic liver failure. In addition, the humanized liver model constructed in this way avoids the use of liver resection surgery, liver-damaging drugs, viruses, bacteria, etc. during the construction process, which may interfere with subsequent applications. It is a more stable model construction method, which is safer than direct intravenous injection and intrasplenic transplantation, improves cell retention rate, reduces adverse reactions, and has great clinical application potential.

[0120] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present application rather than to limit the scope of protection of the present application. Although the present application has been described in detail with reference to the preferred embodiments, ordinary technicians in this field should understand that the technical solution of the present application can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present application.

Claims

1. A method for preparing a cell-complex reconstructed extracellular matrix hydrogel patch, characterized in that: The following steps are involved: S1, taking a tissue block, performing a decellularization treatment on the tissue block to obtain a decellularized scaffold, freeze-drying and grinding the decellularized scaffold to obtain an extracellular matrix powder; digesting the extracellular matrix powder in a digestive solution, and adding oligourethane to mix to obtain a pregel; S2, pre-treating the mesenchymal stem cells, and inducing the pre-treated mesenchymal stem cells to become hepatogenic using the hepatogenic induction composition; Using a first maturation induction composition to perform a first maturation induction on the mesenchymal stem cells that have been subjected to hepatogenesis induction treatment, to obtain hepatocyte-like cells HLCs; using a second maturation induction composition to perform a second maturation induction on the hepatocyte-like cells HLCs, to obtain functional hepatocyte-like cells; S3. Evenly mix the pregel prepared in step S1, mesenchymal stem cells and the functional hepatocyte-like cells prepared in step S2, let stand to solidify, and wait for the functional hepatocyte-like cells to aggregate to form spheres, thereby obtaining a cell-composite reconstructed extracellular matrix hydrogel patch.

2. The method for preparing the cell-complex reconstructed extracellular matrix hydrogel patch according to claim 1, characterized in that: The decellularization process in step S1 includes: The tissue blocks were decellularized using a mixed solution of trypsin and ethylenediaminetetraacetic acid, a camptothecin solution containing penicillin / streptomycin, a sulfobetaine solution, ethylenediaminetetraacetic acid, a mixed solution of DNase and RNase, sodium dodecyl sulfate, Triton X and sodium deoxycholate to obtain a decellularized scaffold.

3. The method for preparing the cell-complex reconstructed extracellular matrix hydrogel patch according to claim 2, characterized in that: The mass concentration of pancreatic enzyme in the mixed solution of pancreatic enzyme and ethylenediaminetetraacetic acid is 0.02%, and the mass concentration of ethylenediaminetetraacetic acid is 0.05%; the mass concentration of camptothecin in the camptothecin solution containing penicillin / streptomycin is 20 μM; the mass concentration of the sulfobetaine solution is 125 mM; the final concentration of DNA enzyme in the mixed solution of DNA enzyme and RNA enzyme is 0.1%, and the final concentration of RNA enzyme is 0.05%; the mass concentration of sodium dodecyl sulfate is 0.1%; the mass concentration of Triton X-100 is 3% and the mass concentration of sodium deoxycholate is 4%.

4. The method for preparing the cell-complex reconstructed extracellular matrix hydrogel patch according to claim 1, characterized in that: In step S2, the reagents for pre-treating the mesenchymal stem cells include 20 ng / mL of epidermal growth factor and 10 ng / mL of basic fibroblast growth factor.

5. The method for preparing the cell-complex reconstructed extracellular matrix hydrogel patch according to claim 1, characterized in that: The hepatogenesis induction composition comprises 30 ng / mL basic fibroblast growth factor, 20 ng / mL hepatocyte growth factor and 0.61 g / L nicotinamide; The first maturation induction composition includes 40 ng / mL of ITS Premix, 10 ng / mL of recombinant human osteoprotegerin-M and 1 μmol / L of dexamethasone; The second maturation induction composition includes 40 ng / mL of ITS Premix, 40 ng / mL of recombinant human osteoprotegerin-M, 1 μmol / L of dexamethasone, 10 μmol / L of human γ-secretase complex inhibitor and 10 μmol / L of small molecule inhibitor SB431542.

6. The method for preparing the cell-complex reconstructed extracellular matrix hydrogel patch according to claim 1, characterized in that: In step S3, the cell density ratio of the mesenchymal stem cells and the functional hepatocyte-like cells prepared in step S2 is 9×10 6 pcs:1×10 6 indivual.

7. The method for preparing the cell-complex reconstructed extracellular matrix hydrogel patch according to claim 1, characterized in that: In the step S3, the pregel prepared in step S1, the mesenchymal stem cells and the functional hepatocyte-like cells prepared in step S2 are mixed evenly with a serum-free medium; The volume ratio of the serum-free culture medium to the pregel is (1-3):(2-4). 8 . The cell-complex reconstructed extracellular matrix hydrogel patch prepared by the method for preparing the cell-complex reconstructed extracellular matrix hydrogel patch according to any one of claims 1 to 7 .

9. A method for constructing a humanized liver animal model, characterized in that: The cell-complex reconstructed extracellular matrix hydrogel patch as claimed in claim 8 is transferred in vivo into FRG immunodeficient animals to obtain a humanized liver animal model.

10. Use of the cell-complex reconstructed extracellular matrix hydrogel patch as claimed in claim 8 in the preparation of a product for treating liver failure.

Citation Information

Patent Citations

  • Method of expanding human hepatocytes in vivo

    CN102460162A

  • Method of printing a tissue construct with embedded vasculature

    CN106163581A

  • Acellular matrix hydrogel as well as preparation method and application thereof

    CN112089890A

  • Preparation method of liver organoid

    CN113388569A

  • Method for removing cells in biological tissue

    CN117582553A